Lemborexant emerged superior to placebo and to a commonly prescribed medication, zolpidem tartrate extended release, in a phase 3 randomized clinical trial of older adults with insomnia.

Four days before release of these results, the US Food and Drug Administration approved lemborexant for treatment of insomnia characterized by difficulties with sleep onset or sleep maintenance, as previously reported by Medscape Medical News.

People randomly assigned to one of two doses of lemborexant, for example, fell asleep faster — and maintained sleep longer — compared with others assigned to placebo or zolpidem.

Get the full story at medscape.com.